Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Cash & Equivalents for 13 consecutive years, with $89.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 16.9% year-over-year to $89.1 million, compared with a TTM value of $89.1 million through Dec 2025, up 16.9%, and an annual FY2025 reading of $89.1 million, up 16.9% over the prior year.
  • Cash & Equivalents was $89.1 million for Q4 2025 at Agios Pharmaceuticals, down from $92.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.9 billion in Q1 2021 and bottomed at $64.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $255.4 million, with a median of $90.9 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents skyrocketed 2019.16% in 2021, then tumbled 95.76% in 2022.
  • Year by year, Cash & Equivalents stood at $203.1 million in 2021, then tumbled by 31.44% to $139.3 million in 2022, then plummeted by 36.66% to $88.2 million in 2023, then dropped by 13.56% to $76.2 million in 2024, then increased by 16.9% to $89.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for AGIO at $89.1 million in Q4 2025, $92.7 million in Q3 2025, and $80.9 million in Q2 2025.